stockrowGRAIL, Inc.
GRAL Healthcare Diagnostics & Research
GRAIL, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $147.2 million, up 17.2% from fiscal 2024.
- Revenue
- +3.71%
- EPS
- +10.2%
- Free cash flow
- −24.9%
Quarter to September 2026, against a year earlier
Follow GRAL
Alert me
GRAIL, Inc. (GRAL) Return on equity
GRAIL, Inc.'s return on equity over the twelve months to 30 September 2026 was −17.3%, down 1.2 percentage points from fiscal 2025 (−16.1%). That is below the Diagnostics & Research industry median of 0.00% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −16.1% | 49.85 |
| FY2024 | −65.9% | (65.92) |
| FY2023 | 0.00% | 0.00 |
| FY2022 | 0.00% | — |
Return on equity against peers
| Company | Return on equity |
|---|---|
| CDNA CareDx, Inc. compare | 33.0% |
| SHC Sotera Health Company compare | 27.0% |
| QGEN QIAGEN N.V. compare | 11.9% |
| VCYT Veracyte, Inc. compare | 9.43% |
| ICLR ICON PLC compare | 4.86% |
| BLLN BillionToOne, Inc. compare | 0.00% |
| RDNT RadNet, Inc. compare | −1.64% |
| GRAL GRAIL, Inc. | −17.3% |
| ADPT Adaptive Biotechnologies Corporation compare | −36.3% |
| Diagnostics & Research industry median | 0.00% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on GRAL
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement